Bioaccumulation of the new antifoulant medetomidine in marine organisms
Résumé
Biofouling is a huge problem globally and new alternative antifoulants are presently being investigated. One candidate is medetomidine, a commonly used sedative in veterinary medicine, which has been shown to effectively prevent settlement of barnacles. The purpose of this study was to measure uptake, elimination and bioconcentration of medetomidine in , , and periphyton communities to evaluate the risk of bioaccumulation in the marine environment. Bioconcentration factors (BCF) and bioaccumulation factors (BAF) were used to assess the bioaccumulation. The calculations of these factors were based on the distribution of the radiolabelled medetomidine. BCF for was 2.8 while had a BCF of 134 and the periphyton communities' BCF was 1195 l/kg fresh weight (FW). The concentration of medetomidine in the animals reached steady state after 24 to 48 hours for all test systems except for , which never stabilised enough to calculate a bioaccumulation factor (BAF). Elimination from the organism's tissues was rapid for three of the test systems with half-lives between 1 and 24 h. had a half-life of 96-120 h. The present study demonstrates that the bioconcentration and bioaccumulation of medetomidine differs between aquatic organisms and that microalgal communities in the form of periphyton have the highest bioconcentration factor of the organisms tested.
Fichier principal
PEER_stage2_10.1016%2Fj.marenvres.2009.03.007.pdf (361.8 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...